Inhibitors

Levofloxacin-¹³C,d₃

Cat. No.: HY-B0330S2 CAS No.: 1261398-33-7

Molecular Formula: $C_{17}^{13}CH_{17}D_{3}FN_{3}O_{4}$

Molecular Weight: 365.38

Target: Bacterial; Antibiotic; Isotope-Labeled Compounds

Pathway: Anti-infection; Others

Storage: Powder -20°C 3 years

In solvent

2 years -80°C 6 months

-20°C 1 month

BIOLOGICAL ACTIVITY

Description	Levofloxacin- ¹³ C,d ₃ is the ¹³ C- and deuterium labeled Levofloxacin.
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs ^[83] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223.

[2]. Lee, B.T., et al., Efficacy of Levofloxacin in the Treatment of BK Viremia: A Multicenter, Double-Blinded, Randomized, Placebo-Controlled Trial. Clin J Am Soc Nephrol, 2014.

[3]. Pradeep, A.R., et al., Clinical and microbiological effects of levofloxacin in the treatment of chronic periodontitis: a randomized, placebo-controlled clinical trial. J Investig Clin Dent, 2014.

[4]. Siva, R., et al., Effect of levofloxacin on neutrophilic airway inflammation in stable COPD: a randomized, double-blind, placebo-controlled trial. Int J Chron Obstruct Pulmon Dis, 2014. 9: p. 179-86.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA